Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2

Author(s)

Rego, Gabriel N. A. ^[1] ; Nucci, Mariana P. ^[2] ; Alves, Arielly H. ^[1] ; Oliveira, Fernando A. ^[1] ; Marti, Luciana C. ^[1] ; Nucci, Leopoldo P. ^[3] ; Mamani, Javier B. ^[1] ; Gamarra, Lionel F. ^[1]

Affiliation

^[1] Hosp Israelita Albert Einstein, BR-05652900 Sao Paulo - Brazil

^[2] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, LIM44, BR-01246903 Sao Paulo - Brazil

^[3] Ctr Univ Planalto, Cent UNICEPLAC, BR-72445020 Brasilia, DF - Brazil

• Document type: Review article
• Source: VACCINES; v. 8, n. 3 SEP 2020.
• Web of Science Citations: 1

Abstract

Coronavirus disease 2019 (COVID-19) is the biggest health challenge of the 21st century, affecting millions of people globally. The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has ignited an unprecedented effort from the scientific community in the development of new vaccines on different platforms due to the absence of a broad and effective treatment for COVID-19 or prevention strategy for SARS-CoV-2 dissemination. Based on 50 current studies selected from the main clinical trial databases, this systematic review summarizes the global race for vaccine development against COVID-19. For each study, the main intervention characteristics, the design used, and the local or global center partnerships created are highlighted. Most vaccine developments have taken place in Asia, using a viral vector method. Two purified inactivated SARS-CoV-2 vaccine candidates, an mRNA-based vaccine mRNA1273, and the chimpanzee adenoviral vaccine ChAdOx1 are currently in phase III clinical trials in the respective countries Brazil, the United Arab Emirates, the USA, and the United Kingdom. These vaccines are being developed based on a quickly formed network of collaboration. (AU)

• FAPESP's process: 14/50983-3 - INCT 2014: complex fluids
• Grantee: Antonio Martins Figueiredo Neto
• Support Opportunities: Research Projects - Thematic Grants